Total Payments
$85,760
2024 Payments
$3,483
Companies
33
Transactions
572
Medicare Patients
2,897
Medicare Billing
$616,407
Payment Breakdown by Category
Other$58,223 (67.9%)
Food & Beverage$20,903 (24.4%)
Consulting$4,915 (5.7%)
Travel$1,089 (1.3%)
Education$625.95 (0.7%)
Gifts$4.91 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $58,223 | 38 | 67.9% |
| Food and Beverage | $20,903 | 499 | 24.4% |
| Consulting Fee | $4,915 | 5 | 5.7% |
| Travel and Lodging | $1,089 | 18 | 1.3% |
| Education | $625.95 | 11 | 0.7% |
| Gift | $4.91 | 1 | 0.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $33,857 | 75 | $0 (2024) |
| Astellas Pharma US Inc | $12,065 | 28 | $0 (2024) |
| Allergan, Inc. | $11,158 | 35 | $0 (2020) |
| Insmed, Inc. | $7,318 | 45 | $0 (2024) |
| Paratek Pharmaceuticals, Inc. | $4,131 | 36 | $0 (2024) |
| ABBVIE INC. | $3,566 | 33 | $0 (2024) |
| Gilead Sciences, Inc. | $2,966 | 82 | $0 (2024) |
| Ferring Pharmaceuticals Inc. | $2,217 | 4 | $0 (2023) |
| ViiV Healthcare Company | $1,738 | 64 | $0 (2024) |
| Melinta Therapeutics, LLC | $1,465 | 45 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $3,483 | 98 | Shionogi Inc ($668.84) |
| 2023 | $7,404 | 81 | Paratek Pharmaceuticals, Inc. ($3,260) |
| 2022 | $2,021 | 62 | Merck Sharp & Dohme LLC ($278.70) |
| 2021 | $4,139 | 55 | AbbVie Inc. ($2,832) |
| 2020 | $7,163 | 45 | Allergan, Inc. ($2,910) |
| 2019 | $25,422 | 95 | Merck Sharp & Dohme Corporation ($13,233) |
| 2018 | $14,022 | 62 | Merck Sharp & Dohme Corporation ($7,571) |
| 2017 | $22,107 | 74 | Merck Sharp & Dohme Corporation ($12,513) |
All Payment Transactions
572 individual payment records from CMS Open Payments — Page 1 of 23
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/23/2024 | Shionogi Inc | Fetroja (Drug) | Food and Beverage | In-kind items and services | $26.44 | General |
| Category: Infections and Infectious Diseases | ||||||
| 12/17/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $19.24 | General |
| 12/10/2024 | Paratek Pharmaceuticals, Inc. | NUZYRA (Drug) | Food and Beverage | In-kind items and services | $4.95 | General |
| Category: ANTIBIOTIC | ||||||
| 11/27/2024 | Merck Sharp & Dohme LLC | DIFICID (Drug), RECARBRIO, ZERBAXA | Food and Beverage | In-kind items and services | $22.42 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 11/27/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $17.27 | General |
| 11/20/2024 | AIMMUNE THERAPEUTICS, INC. | VOWST (Biological) | Food and Beverage | In-kind items and services | $25.95 | General |
| Category: GI | ||||||
| 11/14/2024 | Shionogi Inc | Fetroja (Drug) | Food and Beverage | In-kind items and services | $102.36 | General |
| Category: Infections and Infectious Diseases | ||||||
| 11/13/2024 | Insmed, Inc. | Arikayce (Drug) | Food and Beverage | In-kind items and services | $34.15 | General |
| Category: Respiratory | ||||||
| 11/13/2024 | Shionogi Inc | Fetroja (Drug) | Food and Beverage | In-kind items and services | $25.11 | General |
| Category: Infections and Infectious Diseases | ||||||
| 11/13/2024 | ATRICURE, INC. | ATRICURE CRYOICE CRYOSPHERE CRYOABLATION SYSTEM (Device) | Food and Beverage | In-kind items and services | $14.74 | General |
| Category: CARDIOVASCULAR | ||||||
| 11/06/2024 | Melinta Therapeutics, LLC | Rezzayo (Drug), Kimyrsa | Food and Beverage | In-kind items and services | $28.78 | General |
| Category: ANTIFUNGALS | ||||||
| 11/03/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $14.47 | General |
| 10/30/2024 | ViiV Healthcare Company | DOVATO (Drug) | Food and Beverage | In-kind items and services | $31.33 | General |
| Category: HIV | ||||||
| 10/30/2024 | ViiV Healthcare Company | DOVATO (Drug) | Food and Beverage | In-kind items and services | $3.52 | General |
| Category: HIV | ||||||
| 10/30/2024 | ViiV Healthcare Company | DOVATO (Drug) | Food and Beverage | In-kind items and services | $2.50 | General |
| Category: HIV | ||||||
| 10/29/2024 | Insmed, Inc. | Arikayce (Drug) | Food and Beverage | In-kind items and services | $42.15 | General |
| Category: Respiratory | ||||||
| 10/23/2024 | Merck Sharp & Dohme LLC | PIFELTRO (Drug), DELSTRIGO | Food and Beverage | In-kind items and services | $31.47 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 10/23/2024 | ABBVIE INC. | AVYCAZ (Drug), TEFLARO, DALVANCE | Food and Beverage | In-kind items and services | $28.58 | General |
| Category: ANTI-INFECTIVE | ||||||
| 10/23/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $13.25 | General |
| 10/22/2024 | Shionogi Inc | Fetroja (Drug) | Food and Beverage | In-kind items and services | $26.59 | General |
| Category: Infections and Infectious Diseases | ||||||
| 10/15/2024 | La Jolla Pharmaceutical Company | XERAVA (Drug) | Food and Beverage | In-kind items and services | $38.48 | General |
| Category: TETRACYCLINE CLASS ANTIBACTERIAL | ||||||
| 10/03/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $20.72 | General |
| 10/01/2024 | La Jolla Pharmaceutical Company | XERAVA (Drug) | Food and Beverage | In-kind items and services | $121.84 | General |
| Category: TETRACYCLINE CLASS ANTIBACTERIAL | ||||||
| 09/24/2024 | Insmed, Inc. | Arikayce (Drug) | Food and Beverage | In-kind items and services | $16.85 | General |
| Category: Respiratory | ||||||
| 09/17/2024 | Shionogi Inc | Fetroja (Drug) | Food and Beverage | In-kind items and services | $29.31 | General |
| Category: Infections and Infectious Diseases | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 4 | 626 | 1,540 | $350,456 | $127,339 |
| 2022 | 3 | 698 | 1,674 | $390,934 | $140,400 |
| 2021 | 3 | 807 | 1,942 | $457,754 | $170,419 |
| 2020 | 3 | 766 | 2,066 | $477,198 | $178,249 |
Total Patients
2,897
Total Services
7,222
Medicare Billing
$616,407
Procedure Codes
13
All Medicare Procedures & Services
13 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 286 | 1,144 | $207,064 | $76,545 | 37.0% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 267 | 297 | $125,131 | $42,580 | 34.0% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 47 | 72 | $9,000 | $5,188 | 57.6% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 26 | 27 | $9,261 | $3,027 | 32.7% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 326 | 1,236 | $223,716 | $75,024 | 33.5% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 330 | 380 | $159,968 | $61,002 | 38.1% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 42 | 58 | $7,250 | $4,374 | 60.3% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 371 | 1,407 | $254,667 | $87,322 | 34.3% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 387 | 460 | $193,712 | $77,307 | 39.9% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 49 | 75 | $9,375 | $5,790 | 61.8% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2020 | 359 | 1,579 | $285,799 | $98,772 | 34.6% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2020 | 375 | 441 | $185,649 | $76,690 | 41.3% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 32 | 46 | $5,750 | $2,786 | 48.5% |
About Dr. Jorge Murillo, MD
Dr. Jorge Murillo, MD is a Infectious Disease healthcare provider based in Miami, Florida. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/14/2006. The National Provider Identifier (NPI) number assigned to this provider is 1467496398.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Jorge Murillo, MD has received a total of $85,760 in payments from pharmaceutical and medical device companies, with $3,483 received in 2024. These payments were reported across 572 transactions from 33 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($58,223).
As a Medicare-enrolled provider, Murillo has provided services to 2,897 Medicare beneficiaries, totaling 7,222 services with total Medicare billing of $616,407. Data is available for 4 years (2020–2023), covering 13 distinct procedure/service records.
Ad
Practice Information
- Specialty Infectious Disease
- Location Miami, FL
- Active Since 06/14/2006
- Last Updated 04/15/2011
- Taxonomy Code 207RI0200X
- Entity Type Individual
- NPI Number 1467496398
Products in Payments
- ZERBAXA (Drug) $17,398
- DIFICID (Drug) $12,313
- CRESEMBA (Drug) $8,148
- DALVANCE (Drug) $7,035
- AVYCAZ (Drug) $4,557
- NUZYRA (Drug) $4,131
- Arikayce (Drug) $3,204
- Cresemba (Drug) $3,143
- REBYOTA (Biological) $2,217
- DOVATO (Drug) $1,320
- Fetroja (Drug) $862.04
- Biktarvy (Drug) $823.53
- Vabomere (Drug) $737.93
- PREZCOBIX (Drug) $624.56
- XERAVA (Drug) $574.65
- Epclusa (Drug) $455.83
- Baxdela (Drug) $428.32
- XACDURO (Drug) $331.46
- SYMTUZA (Drug) $318.51
- VIBATIV (Drug) $285.57
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Infectious Disease Doctors in Miami
Douglas Brust, M.d, M.D
Infectious Disease — Payments: $450,213
Infectious Disease $450,213
Ricardo Fonseca Franco
Infectious Disease — Payments: $135,298
Infectious Disease $135,298
Hector Bolivar, Md, MD
Infectious Disease — Payments: $105,997
Infectious Disease $105,997
Dushyantha Jayaweera, Md, MD
Infectious Disease — Payments: $79,219
Infectious Disease $79,219
Dr. Lilian Abbo, Md, MD
Infectious Disease — Payments: $69,205
Infectious Disease $69,205
Mrs. Vanessa Silebi, Md, MD
Infectious Disease — Payments: $67,359
Infectious Disease $67,359